Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Frost

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Lancet (London, England)|January 15, 2013
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trialJohn J Bissler, J Christopher Kingswood, Elżbieta Radzikowska, et al.
Acta Neuropathologica Communications|October 30, 2024
NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomesMichael Chang, Mohamed Sherief, Maria Ioannou, et al.
The Medical Journal of Australia|June 17, 2026
Continuity of Care in General Practice in Australia: A Whole-Of-Population Serial Cross-Sectional StudyJennifer Welsh, Rachel Freeman-Robinson, Danielle C Butler, et al.
Lancet (London, England)|November 20, 2012
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Health Care Transitions|June 19, 2026
An e-health transition intervention for youth with brain-based disabilities: Pilot and feasibility results from a Randomized Controlled TrialJan Willem Gorter, Ronen Rozenblum, Adrienne H Kovacs, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Lancet (London, England)|January 15, 2013
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trialJohn J Bissler, J Christopher Kingswood, Elżbieta Radzikowska, et al.
Acta Neuropathologica Communications|October 30, 2024
NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomesMichael Chang, Mohamed Sherief, Maria Ioannou, et al.
The Medical Journal of Australia|June 17, 2026
Continuity of Care in General Practice in Australia: A Whole-Of-Population Serial Cross-Sectional StudyJennifer Welsh, Rachel Freeman-Robinson, Danielle C Butler, et al.
Lancet (London, England)|November 20, 2012
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trialDavid Neal Franz, Elena Belousova, Steven Sparagana, et al.
Health Care Transitions|June 19, 2026
An e-health transition intervention for youth with brain-based disabilities: Pilot and feasibility results from a Randomized Controlled TrialJan Willem Gorter, Ronen Rozenblum, Adrienne H Kovacs, et al.
Pageof 4